SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
AB Science Reports Positive Clinical Study Data: Masitinib Significantly Extends Overall Survival as Compared to Pfizer Inc.'s Sutent®in Gleevec®-resistant GIST